Quick Takeaways
- GILEAD SCIENCES, INC. filed SCHEDULE 13D/A for Assembly Biosciences, Inc. Common Stock, par value $0.001 (ASMB).
- Disclosed ownership: 30%.
- Date of event: 19 Dec 2024.
GILEAD SCIENCES, INC. - 19 Dec 2024 SCHEDULE 13D/A Report for Assembly Biosciences, Inc. Common Stock, par value $0.001 (ASMB)
- Filing Manager
- GILEAD SCIENCES, INC.
- Reporting Manager
- Gilead Sciences, Inc.
- Symbol
- ASMB
- Shares outstanding
- 7,389,535 shares
- Disclosed Ownership
- 2,209,471 shares
- Ownership
- 30%
- Form type
- SCHEDULE 13D/A
- Filing time
- 23 Dec 2024, 20:17:49 UTC
- Date of event
- 19 Dec 2024
- Next filing
- 12 Aug 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"GILEAD SCIENCES, INC. disclosed 30% ownership in Assembly Biosciences, Inc. Common Stock, par value $0.001 (ASMB) on 19 Dec 2024."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 23 Dec 2024, 20:17.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. | 30% | 2,209,471 | 2,209,471 | 0 | /s/ Andrew D. Dickinson | Andrew D. Dickinson, Chief Financial Officer | 0000882095 |